In the analysis of clinicopathological characteristics, MYL9 expression was closely related to the tumor TNM stage in bladder urothelial carcinoma, adrenocortical carcinoma, stomach adenocarcinoma, and thyroid carcinoma (Figure S1B). Here, MYL9 is linked to bladder transitional cell carcinoma.